Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 31, 2012. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares in accordance with shareholder authority granted at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share repurchase activity and capital structure updates.
- Shares Purchased: 1,500,000 Ordinary Shares of 25 pence each.
- Purchase Date: October 31, 2012.
- Price Range: Highest price paid was 1,425 pence per share; lowest price paid was 1,385.5 pence per share.
- Treasury Holdings (Settled): 516,290,427 shares (9.48% of total issued share capital).
- Treasury Holdings (Including Unsettled): 519,790,427 shares (10.55% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,929,058,597 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the repurchase of 1,500,000 shares on October 31, 2012. Consequently, the percentage of shares held in Treasury increased to 9.48% of total issued share capital, and the percentage of total voting rights held in Treasury (including unsettled shares) reached 10.55%.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance announcement confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules and explicitly states it does not constitute an offer or solicitation to purchase securities.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (516,290,427 settled) against the company's latest capitalization table.
- Confirm the calculation of total voting rights (4,929,058,597 shares in issue) for disclosure threshold assessments.
- Review the price paid per share (1,385.5 to 1,425 pence) to assess the cost of capital return relative to market prices on October 31, 2012.
- Check for subsequent filings regarding the settlement of the 3,500,000 shares mentioned as "purchased but not yet settled" in the total treasury count.